TOTAL VOLUME:
$166.8b
24H VOL:
$89,987,006
24H TRANSACTIONS:
3,258,908,236
OPEN INTEREST:
$1,696,807,265
332,071
Markets across
35,607
events
MATCHED EVENTS:
3,434
PLATFORM COVERAGE:
5
Polymarket:
36%
VS.
Kalshi:
64%
6000+
- Polymarket
6000+ - Polymarket
1W
News
Positive
Negative
Neutral
Hover marker for details
Vol.
·
Resolves Nov 30, 2026
Time left: 08d:16h:12m
$
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026, according to the CDC case counter by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Measles (Rubeola) counter 'Total Cases' in 2026 (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
This market will resolve to "Yes" if there have been the specified amount or more confirmed cases of Measles (Rubeola) in humans in the territory of the United States of America in 2026, according to the CDC case counter by November 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The resolution source for this market will be the CDC Measles (Rubeola) counter 'Total Cases' in 2026 (see: https://www.cdc.gov/measles/data-research/index.html) at the resolution time. If the counter becomes unavailable, another credible source will be used. Note: Only cases reported by the CDC Measles (Rubeola) counter will qualify, regardless of reports from U.S. State agencies or other sources.
Currently, the prevailing sentiment in this market suggests a very high probability of a significant number of measles cases. This contrasts with some early-year analyst forecasts which predicted a more contained outbreak due to vaccination rates. However, recent reports of localized outbreaks have shifted public health discussions. It's important to note that prediction markets like this one reflect a collective intelligence, incorporating a wider range of information and perspectives than traditional forecasts. The market’s current pricing suggests a different expectation than initial analyses regarding the U.S. measles case count.
On Polymarket, this market is priced through a continuous trading mechanism where participants buy and sell shares representing their belief about the final U.S. measles case count. The price of these shares fluctuates based on supply and demand, effectively creating a probability estimate. On Polymarket, prices reflect that venue's order book, liquidity, and how traders price the outcome right now. The current top outcome, 'Will there be at least 4600 measles cases in the U.S. by November 30, 2026?', has a chance percentage of 91.0%. This reflects the aggregated views of traders on Polymarket regarding the potential scale of the measles outbreak.
This market resolves around Dec 1, 2026, with the outcome confirmed once the event is verifiable from credible public reporting. The final U.S. measles case count will be determined by data reported by official public health organizations, such as the Centers for Disease Control and Prevention (CDC). The resolution will be based on the total number of confirmed measles cases reported within the United States by that date, providing a definitive answer to the question posed by this market.
Several factors could significantly impact this market. A substantial increase in measles outbreaks in highly populated areas would likely drive up the price of shares representing a higher case count. Conversely, a successful nationwide vaccination campaign or the rapid containment of existing outbreaks could lower those prices. Public health announcements from organizations like the CDC, changes in vaccination policies, and even media coverage influencing public perception could all move this market. Monitoring these signals will be crucial for understanding the evolving expectations surrounding the U.S. measles case count.